{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:02:35Z","timestamp":1780380155110,"version":"3.54.1"},"reference-count":30,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1136\/jnnp-2011-300376","type":"journal-article","created":{"date-parts":[[2012,8,29]],"date-time":"2012-08-29T21:08:04Z","timestamp":1346274484000},"page":"1138-1147","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":97,"title":["KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy"],"prefix":"10.1136","volume":"84","author":[{"given":"Eugen","family":"Trinka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Paesschen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetta","family":"K\u00e4lvi\u00e4inen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Marovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Buyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yngve","family":"Hallstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Hon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Carlo","family":"Muscas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Joachim","family":"Meencke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Pohlmann-Eden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the KOMET Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,8,29]]},"reference":[{"key":"key-10.1136\/jnnp-2011-300376-1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756285608094212","article-title":"Review: is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited","volume":"1","author":"Surges","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"key":"key-10.1136\/jnnp-2011-300376-2","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key-10.1136\/jnnp-2011-300376-3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"key-10.1136\/jnnp-2011-300376-4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-5","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"key-10.1136\/jnnp-2011-300376-6","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-7","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-8","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-9","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/j.1528-1167.2008.01618_2.x","article-title":"Clinical relevance of patients with epilepsy included in clinical trials","volume":"49","author":"Tlusta","year":"2008","journal-title":"Epilepsia"},{"key":"key-10.1136\/jnnp-2011-300376-10","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1212\/WNL.49.2.333","article-title":"Difficulties in extrapolating from clinical trial data to clinical practice: the case of antiepileptic drugs","volume":"49","author":"Walker","year":"1997","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-11","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2011-300376-12","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","article-title":"The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"key-10.1136\/jnnp-2011-300376-13","first-page":"1","article-title":"Erster epileptischer Anfall und Epilepsien im Erwachsenenalter","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie im der Neurologie","author":"Elger","year":"2008"},{"key":"key-10.1136\/jnnp-2011-300376-14","unstructured":"National Institute for Health and Clinical Excellence (NICE). The Epilepsies: Pharmacological Management of the Epilepsies in Adults and Children in Primary and Secondary Care (Partial Update of NICE Clinical Guideline 20), 2009."},{"key":"key-10.1136\/jnnp-2011-300376-15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","author":"International League Against Epilepsy","year":"1981","journal-title":"Epilepsia"},{"key":"key-10.1136\/jnnp-2011-300376-16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1212\/01.wnl.0000172932.95985.51","article-title":"Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine","volume":"65","author":"Ficker","year":"2005","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00228-006-0175-2","article-title":"Conventional and sustained-release valproate in children with newly diagnosed epilepsy: a randomized and crossover study comparing clinical effects, patient preference and pharmacokinetics","volume":"62","author":"Herranz","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.1136\/jnnp-2011-300376-18","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.yebeh.2006.02.006","article-title":"Conversion from delayed-release sodium valproate to extended-release sodium valproate: initial results and long-term follow-up","volume":"8","author":"McCabe","year":"2006","journal-title":"Epilepsy Behav"},{"key":"key-10.1136\/jnnp-2011-300376-19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1600-0404.2004.00291.x","article-title":"Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine","volume":"109","author":"Miller","year":"2004","journal-title":"Acta Neurol Scand"},{"key":"key-10.1136\/jnnp-2011-300376-20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.yebeh.2004.07.007","article-title":"Clinical comparison of extended-release divalproex versus delayed-release divalproex: pooled data analyses from nine trials","volume":"5","author":"Smith","year":"2004","journal-title":"Epilepsy Behav"},{"key":"key-10.1136\/jnnp-2011-300376-21","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1212\/01.WNL.0000163771.96962.1F","article-title":"Antiepileptic drug use of women with epilepsy and congenital malformations in offspring","volume":"64","author":"Artama","year":"2005","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.2005.074203","article-title":"Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register","volume":"77","author":"Morrow","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key-10.1136\/jnnp-2011-300376-23","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1212\/01.WNL.0000154516.43630.C5","article-title":"Increased rate of major malformations in offspring exposed to valproate during pregnancy","volume":"64","author":"Wyszynski","year":"2005","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"key-10.1136\/jnnp-2011-300376-25","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/j.1528-1167.2010.02668.x","article-title":"Early cognitive development in children born to women with epilepsy: a prospective report","volume":"51","author":"Bromley","year":"2010","journal-title":"Epilepsia"},{"key":"key-10.1136\/jnnp-2011-300376-26","first-page":"245","article-title":"UCB Antiepileptic drug pregnancy registry","volume":"50","author":"Alekar","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"key-10.1136\/jnnp-2011-300376-27","first-page":"P44","article-title":"Levetiracetam therapy in human pregnancy. Updated experience from the UK Epilepsy and pregnancy register","volume":"50","author":"Hunt","year":"2009","journal-title":"Epilepsia"},{"key":"key-10.1136\/jnnp-2011-300376-28","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1212\/WNL.0b013e3182088297","article-title":"Child development following in utero exposure: levetiracetam vs sodium valproate","volume":"76","author":"Shallcross","year":"2011","journal-title":"Neurology"},{"key":"key-10.1136\/jnnp-2011-300376-29","unstructured":"Shallcross R, Bromley R, Irwin B, et al. A first look at the language and developmental abilities of children aged three to four years exposed in utero to Levetiracetam [Abstract]. AES 2010; Abstract 1.312. http:\/\/www.aesnet.org\/go\/publications\/aes-abstracts\/abstract-search\/mode\/display\/st\/Shallcross\/sy\/2010\/sb\/All\/id\/12512"},{"key":"key-10.1136\/jnnp-2011-300376-30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/j.1528-1167.2006.00585.x","article-title":"ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"47","author":"Glauser","year":"2006","journal-title":"Epilepsia"}],"container-title":["Journal of Neurology, Neurosurgery & Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2011-300376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:44:40Z","timestamp":1601041480000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2011-300376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,29]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2013,9,2]]},"published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1136\/jnnp-2011-300376"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2011-300376","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8,29]]}}}